{
  "nctrialId": "HC-1526",
  "title": "A Randomized Open-Label, Placebo-Controlled Multi-Center Study of DMD-551 (exon-skipping antisense oligonucleotide) in Patients With Parkinson's Disease",
  "officialTitle": "A Randomized Open-Label, Placebo-Controlled Multi-Center Study of DMD-551 (exon-skipping antisense oligonucleotide) in Patients With Parkinson's Disease",
  "sponsor": "Alberta Health Services",
  "indication": "Parkinson's Disease",
  "phase": "Phase 1/Phase 2",
  "fileName": "HC-1526.json",
  "fileSize": 120081,
  "date": "2024-02-23",
  "completionDate": "2025-08-01",
  "drugName": "DMD-551 (exon-skipping antisense oligonucleotide)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Terminated",
  "description": "This is a randomized open-label, placebo-controlled multi-center study designed to evaluate the efficacy and safety of DMD-551 (exon-skipping antisense oligonucleotide) in patients with Parkinson's Disease. The study will enroll approximately 275 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 18-61 years\n- Confirmed diagnosis of Parkinson's Disease\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}